Purine and Pyrimidine Metabolism Flashcards
The reactions catalyzed by HGPRT
HGPRT defeciency
In general: Synthesis of Nucleotides from Free bases
HGPRT an enzyme required for the synthesis of IMP and GMP
IMP free base is hypoxanthine
GMP free base is guanine
Defeciency can result in Lesch-Nyhan Synd.
Name the enzyme and the by-product
Guanosine E1→ Guanine + X
Inosine E2→ Hypoxanthine + X
In both rxns:
nucleoside → Free base
Both E1 & E2 :
Purine nucleo_side_ Phosphory_lase-_ PNP
Phosphoribosyl transferase
Major Pathway
Rxns catalyzed by this enzyme
Purine Salvg Pthwy
- Addition of Ribose-5P to a Basefree
- PRPP + Basefree → Nuctide** + PPi**
The enzyme that catalyzes the phosphorolysis of N-glycosidic bond:
Phosphorolysis of N-glycosidic bond is catalyzed by purine nucleoside phosphorylase (PNP)
Guanosine PNP→ guanine + R-1P
Inosine PNP→ hypoxanthine + R-1P
- Ribose 1-posphate can be isomerized to ribose 5-phosphate (R1P ⇔ R5P )
- Free bases (Bf or Basefree) can be salvaged ordegraded
- The reactions are part of purine Salvage Pathway (PuSP)
Three groups of enzymes that participate in Pu.SPs
- Deaminase (DAs): AMP-DA and Adenosine Deaminase (ADA)
Pt. w/ Ø ADA1- SCID & 1st Increased [dA] → [ATP] inc.
- PhosphoRibosyl Transferease (PRT): HGPRT and APRT
Pt. w/ Ø HGPRT - Inc. [UA] bc . exc. degrd . Purines (free bases) since they cnt b rcycld
- Purine nucleoside Phosphorylase (PNP)
ADA1 Ø
Possible causes of delay in SCID detection (1/100 K live births
In N/H. (normal and healthy) indiv:
- Adenosine ADA1→ Inosine
- dAdenosine ADA1→ dInosine <span>Deoxyinosine is found in DNA while inosine is found in RNA.)</span>
In ADA1Ø indiv:
dA builds up (dA convrts to dATP) leads to dATP accumulation.
dATP accumulation leads to reduced doxynucleotides, which impairs lymphocyte proliferaiton. ADA-deficient are SCID and are unable to produce significant numbers of mature T or B lymphocytes.
ADA1 Ø & _ribonucleotide diphosphate reductase (rNDP)_
ADA1 Ø causes an increase in dA and dATP conc.
Accumulated dATP inhibits rNDP.
rNDP substrates
ADP, GDP, UDP, CDP
Ribonucleotide reductase (RNR), also known as ribonucleoside diphosphate reductase (rNDP), is an enzyme that catalyzes the formation of deoxyribonucleotides from ribonucleotides
The portion of salvage pathway that is important for muscle tissue
Brief discription
Purine Nucleotide Cycle
Fumarate production as a result of AMP build-up, and its conversion to IMP in excercising muscle.
AMP also activates PFK-1 and glycogen phosphorylase b (glycolysis and glycogenolysis activation)
AMP deaminase Ø
Deficiency of AMP deaminase results in muscle fatigue during exercises (from 1 in 50 to 1 in 40,000 people).
Generation of ATP
(high intensity exercise)
During high intensity exercise cytosolic ATP is rapidly converted to ADP.
Direct generation of ATP from ADP by:
myokinase (adenylate kinase)
2ADP ⇔ ATP + AMP
Note: removing AMP causes right shift. One possible way, removing AMP by AMP deaminase
The reason for ammonia accumulation in exercising muscles
Because of the increased levels of AMP and IMP.
Degradation of purines is linked to the generation of ATP. During high intensity exercise cytosolic ATP is rapidly converted to ADP. ATP can be generated directly from ADP by myokinase (adenylate kinase):
2ADP⇔ ATP + AMP
The reaction is driven to the right by AMP deaminase (high conc. in skeletal muscle)
AMP + H2O → IMP + NH3
muscle AMP deaminase deficiency
Defective gene (inheritance pattern)
Sx
Exacerbation of the Sx
- AMPD1 gene
- fatigue, muscle weakness, cramps, pain and other muscle prob.
- Statins exacerbate the symptoms
Synthesis of pyrimidines
Base synthesized first
Produced from Asp and carbamoyl phosphate (from CO2 and Gln by CPSII)
The first three enzymes: CAD
CPSII analogous
Analogous to urea cycle CPS I
Unlike its analogous, CPSII uses Gln as source of N and occurs in cytosol
The first three enzymes of pyrimidine synthesis
CAD
- Carbamoyl phosphate synthetase II
- Asp transcarbamoylase
- Dihydro-orotase
Regulated Step of Pyrimidine Synthesis
production of carbamoyl phosphate catalized by CPS II.
CPS II activity: + PRPP, - UTP
[CPS II-P] made by MAP kinase increases CPSII responsiveness to PRPP (inc the prob. of activation)- During S-phase.
Folate deficiency can result in anemia (macrocytic or megaloblastic) because of limited dTMP syn.
An activator of CPSII
PRPP
Orotic acid (orotate) conversion to UMP
2 enzymes, 1 polypeptide, UMP synthase
UMP synthase Ø
leads to:
Hereditary orotic aciduria, megaloblastic anemia and growth retardation (red. Py.Synth.)
Treatment:
Oral uridine ( Uridine is converted to UMP bypassing metabolic block)
Causes of Orotic Aciduria
1- UMP synthase deficiency
2- Ornithine transcarbomylase def. (Urea Cycle)- leads to carbomyl phosphate accuml. in Mt. which leaks to the cytoplasm (bypasses the rxn catalyzed by CPSII)
Synthesis of deoxyribonucleotides occurs at—————- level.
diphosphate
CTP and dCTP production
CTP is produced by an addition of amino group from Gln to C4 of UTP
UTP and CTP are precursors of for RNA synthesis
CDP RR→ dCDP
Ribonucleotide reductase (RR)
dUDP synthesis
UDP RR→ dUDP
Ribonucleotide reductase (RR)
RR also syntheses dCTP
Ribonucleotide reductase (RR)
UDP/CDP RR→ dUDP/dCDP
Synthesis of dUDP and dCDP
dTTP Synthesis
dTTP is produced by methylation of dUMP
thymidylate synthase from N5,N10-methylene-THF
Synthesis of CTP, dCTP, and dTTP
CTP is produced by an addition of amino group from Gln to C4 of UTP
dCTP and dUDP synthesised by RR
dTTP is produced by methylation of dUMP ( catalyzed thymidylate synthase from N5,N10-methylene-THF).
Inhibitor of thymidylate synthase
(aticancer)
5-fluorouracil
No dTMP synthesis – arrest of cell division
Inhibitor of dihydrofolate reductase
(anticancer)
Methotrexate (antifolate drug)
Anticancer drugs
(target enzymes of pyrimidine synthesis)
5-fluorouracil inhibits thymidylate synthase (No dTMP)
Methotrexate inhibits dihydrofolate reductase (blocks recycling of 5,10-methylese-FH4.
Antifolate drug)
mechanism of methotrexate action
Conditions treated by it
- An inhibition of purine and pyrimidine synthesis.
- Reduction of antigen-dependent T-cell proliferation.
- Promotion of adenosine release with adenosine-mediated suppression of inflammation.
antiintlammatory effects
- cancer, severe Psoriasis, RA, Systemic Lupus Erythematosus
The enzymes of the Py. Salv. Pth
nucleoside phosphorylases (base ⇔ nucleoside)
nucleoside + P ⇔ Base + R1-P
nucleoside kinases
Pyrimidine Salvage Pathway
Pyrimidine bases are salvaged by two-step route:
Nucleoside phosphorylase adds deoxyribose residue.
Thymine phosphorylases uses deoxyribose 1-phosphate as a substrate.
Nucleoside phosphorylase can catalyze the reversible reaction:
nucleoside + phosphate ⇔ base +ribose 1-phosphate
A specific nucleoside kinases convert nucleosides to nucleotides.
b-aminoisobutyrate & b-alanine
Found in urine- pyrimidine degradation
- nucleoside formation- remove P from pyrimidine nucleotides
- nucleoside cleavage (R1P and base)
- degrade bases
- Cytosine deamination →B-alanine
- Thymine → B-aminoisobutyrate
ribonucleotide reductase
NDPs are substrates to make dNDPs
Reduction of ribose to deoxyribose:
Occurs on the diphosphate level
The reaction is catalyzed by ribonucleotide reductase
Regulation of ribonucleotide reductase
Allosteric regulation
Coenzyme/cofactors
A- two allosteric sides:
1- activity
ATP activates
dATP inhibits
2- specificity
B- thioredoxin and NADPH
Regulation of Specificity
ribonucleotide reductase
Binding of ATP, dTTP, or dGTP to substrate specificity site determines what substrate can binds to the active site.
To adjust the affinity for less abundant dNTPs
Degradation of Purine Bases
Degradation of Purine Bases
mainly in the liver.
Produces two free bases: guanine and hypoxanthine.
Hypoxanthine xanthine oxidase→xanthine
Guanine guanase→xanthine
Xanthine is converted to uric acid and excreted in urine.
Xanthine <strong>xanthine oxidase/dehydrogenase</strong> → Uric acid
Its increased activity has been associated with hypercholesterolemia.
uric acid, urate (increased level)
Uric acid is a final product of purine degradation in humans. Uric acid forms urate at physiological pH.
Urate is not very soluble in aq. solutions.
Normal [urate]bld is very close to Ksp.
Increased [urate] (hyperuricemia) can lead to the formation and deposition of urate crystals in tissues and joint.
Some disorders that causes overproduction of purines
PRPP synthetase overactivity
Glucose-6-phosphatase deficiency (vonGierke disease)
Gout management
- Acute gout attack by NSAIDs (ibuprofen) or injection of glucocorticoids into joints to manage inflammation.
- Lowering uric acid level by using the inhibitors of xanthine oxidase (alluporinol or oxipurinol) or uricosuric drugs that increase excretion of uric acid in urine (should not be used in persons with already high urine concentration of uric acid).
- Dietary changes: by limiting consumption of alcohol (lactate production) and purine-rich food (meat, fish, spinach, and dry beans)
Alcohol promotes ATP turnover leading to an increased degradation of purines.
Lactate increases uric acid renal reabsorption.
inhibitors of xanthine oxidase
alluporinol
oxipurinol
uricosuric drugs
lowers uric acid conc. in urine
obesity and hyperuricemia
Obese people tends to have high plasma level of urate
Diet and hyperuricemia
subjects with high protein diet ,which is also rich in nucleic acids, and with high alcohol consumption have high levels of plasma urate
alcohol consumption and hyperuricemia
Oxidation of alcohol generates acetate that is converted to acetyl-CoA, which increases adenine nucleotide turn over by increasing consumption of ATP.
ATP + Acetate + CoA ⇔ AMP + Pyrophosphate + Acetyl-CoA
Xanthinuria
This is a rare hereditary disorder in which there is a mutations in liver xanthine dehydrogenase gene or the molybdenum cofactor gene.
The catabolism of purine stops at the xanthine and hypoxanthine compounds.
The blood uric acid is very low.
Increased excretion of urinary xanthine.
This may lead to the formation renal xanthine stones.
Reduced excretion of urinary uric acid.
Diseases Associated with Reduced Uric Acid Levels
Diseases Associated with Elevated Uric Acid Levels
Gout, CVD, hYPERtension(renal)
Increasing Uric Acid Concentrations as a Treatment for:
SC injory, MS (other neurological cond.)
Decreasing Uric Acid Concentrations as a Treatment for:
Gout, CVD, HyperTension
Allopurinol and Xanthine
Allopurinol (a structural analogue of hypoxanthine) is a substrate for xanthine oxidase.
Converted to Oxypurionol (inhibits xanthine oxidase).
Redction in UA production
Degraded purines are spread over three products
hypoxanthine, xanthine, and uric acid
Rapid decrease in uric acid level
Rapid decrease in uric acid level can lead to quick dissolution of urate crystals, which would triggers proinflammatory cytokine production and development of inflammation
Disorder of purine and pyrimidine metabolism: gount
Gene defect
Accumulated metabolite
Clinical Sx
Disorder of purine and pyrimidine metabolism: SCID
Gene defect
Accumulated metabolite
Clinical Sx
Disorder of purine and pyrimidine metabolism: immunodeficiency disease
Gene defect
Accumulated metabolite
Clinical Sx
Disorder of purine and pyrimidine metabolism: lesh-nyhan syndrome
Gene defect
Accumulated metabolite
Clinical Sx
Disorder of purine and pyrimidine metabolism: hereditary orotic aciduria
Gene defect
Accumulated metabolite
Clinical Sx
Disorder of purine and pyrimidine metabolism: xanthinuria
Gene defect
Accumulated metabolite
Clinical Sx
Disorder of purine and pyrimidine metabolism: Exercise induced myopathy
Gene defect
Accumulated metabolite
Clinical Sx